RUPATADINE FUMARATE: NEW FORMULA - NEW THERAPEUTIC EFFICACY



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Rupatadine is a newly synthesized formula combining molecules selectively inhibiting peripheral H 1 receptors and the receptors for the platelet-activating factor. This unique combination allows suppressing the early and late phases of allergic reactions. High efficacy, non-sedating properties, possibility of high doses treatment, absence of side effects of rupatadine has been investigated for treatment of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents in several controlled studies, showing a rapid onset of action and a good safety profile even in prolonged treatment periods.

Full Text

Restricted Access

About the authors

M A Mokronosova

Mechnikov's Research Institute for vaccines and sera, Department of Clinical Allergology

Email: mmokronosova@mail.ru
Moscow, Russia

References

  1. Jutel M., Akdis M., Akdis C.A. Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy. 2009, v. 39, р. 1786-800.
  2. Church M.K., Maurer M. Antihistamines. Chem. Immunol Allergy. 2014, v. 100, р. 302-310.
  3. Benveniste J. Platelet-activating factor (PAF-acether): present status. Agents Actions. 1981, v. 11, р. 542-544.
  4. Benveniste J., Henson P.M., Cochrane C.G. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J. Exp. Med. 1972, v. 136, р. 1356-1377.
  5. Demopoulos C.A., Pinckard R.N., Hanahan D.J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glycer-yl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J. Biol. Chem. 1979, v. 254, р. 9355-9358.
  6. Queralt M., Merlos M., Giralt M., Puigdemont A. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug. Dev. Res. 1996, v. 39, р. 12-18.
  7. Page C.P The role of platelet activating factor in allergic respiratory disease. Br. J. Clin. Pharmacol. 1990, v. 30, р. 99-106.
  8. Keam S.J., Plosker G.L. Rupatadine: A review of its use in the management of allergic disorders. Drugs. 2007, v. 67, р. 457-474.
  9. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert. Opin. Pharmacother. 2006, v. 7, р. 1989-2001.
  10. Queralt M., Brazis C., Merlos M., Puigdemont A. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum in hypersensitive dogs. Drug. Dev. Res. 1998, v. 44, р. 49-55.
  11. Allergic Rhinitis and its Impact on Asthma (ARIA) 2010 revision. World Health Organization (WHO). 2010, 153 p.
  12. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Global allergy and asthma European Network; Grading of recommendations assessment, development and evaluation working group. J. Allergy Clin. Immunol. 2010, v. 126, р. 466-476.
  13. Zuberbier T., Aberer W., Asero R., Bindslev-Jensen C. et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014, v. 69, р. 868-887.
  14. Metz M., Maurer M. Rupatadine for the treatment of allergic rhinitis and urticaria. Expert. Rev. Clin. Immunol. 2011, v. 7, р. 15-20.
  15. Marmouz F. Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial. J. Asthma and Allergy. 2011, v. 4, р. 1-10.
  16. Stuebner P., Horak F., Zieglmayer R. et al. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann. Allergy Asthma lmmunol. 2006, v. 96, р. 37-44.
  17. Fantin S., Maspero J., Bisbal C. et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008, v. 63, р. 924-931.
  18. Saint-Martin F., Dumur J.P., Pérez I., Izquierdo I. French Rupatadine-Rhinitis Study Group. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Invest. Allergol Clin. Inmunol. 2004, v. 14, р. 34-40.
  19. Kowalski L. Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: a randomized, double-blind, controlled trial with loratadine and placebo. Therapy. 2009, v. 6, р. 417-425.
  20. Maiti R. Rupatadine and levociterizine for Seasonal Allergic Rhinitis. A comparative study for efficacy and safety. Arch. Otolaryngol. Head Neck Surg. 2010, v. 136, р. 796-800.
  21. Valero A., Izquierdo I., Giralt J. et al. Rupatadine improves nasal symptoms, quality of life (ESPRINT-15), and severity in a cohort of Spanish allergic rhinitis patients. J. Allergy Clin. Immunol. 2011, v. 21, р. 229-235.
  22. Nettis E., Delle Donne P., Di Leo E. et al. Rupatadine for the treatment ofurticaria. Expert. Opin. Pharmacother. 2013, v. 14, р. 1807-1813.
  23. Dubertret L., Zalupca L., Cristodoulo T. et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, doubleblind, placebo-controlled study. Eur. J. Dermatol. 2007, v. 17, р. 223-228.
  24. Gimenez-Arnau1 A., Pujol R.M., Ianosi S. et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007, v. 62, р. 539-546.
  25. Metz M., Scholz E., Ferran M. et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann. Allergy Asthma Immunol. 2010, v. 104, р. 86-92.
  26. Siebenhaar F., Förtsch A., Krause K. et al. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013, v. 68, р. 949-952.
  27. Karppinen A., Brummer-Korvenkontio H., Reunala T., Izquierdo I. Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy. J. Eur. Acad. Dermatol Venereol. 2012, v. 26, р. 919-922.
  28. Barbanoj M.J., García-Gea C., Morte A. et al. Central and peripheral evaluation of rupatadine, a new antihistamine/ platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 2004, v. 50, р. 311-321.
  29. Donado E. No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study performed according to ICH guidelines. Br. J. Clin. Pharmacol. 2010, v. 69, р. 401-410.
  30. Solans A., Carbó M., Peña J. et al. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. Clin. Therapeutics. 2007, v. 29, р. 900-908.
  31. Vuurman E., Theunissen E., van Oers A. et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum. Psychopharmacol. 2007, v. 22, р. 289-297.
  32. Barbanoj M.J. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum. Psychopharmacol. 2006, v. 21, р. 13-26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2014



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies